Advantages of ebastine in the treatment of chronic urticaria

Orlova E.A., Kandrashkina Yu.A., Kostina E.M., Vikhreva M.N.

1) Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education, Penza, Russia; 2) Penza State University, Penza, Russia

Chronic urticaria (CU) is a condition caused by known and unknown causes, characterized by the appearance of wheals or angioedemas, each lasting no more than 24 hours, daily or almost daily for more than 6 weeks. Most cases of CU include chronic spontaneous urticaria (CSU), which has no apparent external cause and occurs without any specific external trigger, while induced urticaria (CIU) is caused by a specific external stimulus. In one-third of patients, the disease may occur in a combined form of CSU and CIU Combined forms of urticaria (CSU+CIU) are a condition characterized by a more severe course and treatment resistance. Comorbid associations of several CIU have been described, but large-scale studies of the prevalence and evaluation of treatment efficacy for such combinations have not been conducted. Ebastine is an antihistamine suitable for use in urticaria. The study was aimed to demonstrate the efficacy of ebastine in patients with various types of urticaria. In the treatment of CSU, the drug demonstrates high clinical efficacy at standard doses. This article demonstrates the efficacy of ebastine in various urticaria phenotypes, including comorbid CSU and CIU. The efficacy and reliable safety profile of standard doses of ebastine in the treatment of CSU, and in more complex cases (combined forms of urticaria) – escalated cases—provides disease control, which allows ebastine to be recommended as the drug of choice.

For citations: Orlova E.A., Kandrashkina Yu.A., Kostina E.M., Vikhreva M.N. Advantages of ebastine in the treatment of chronic urticaria. Pharmateca. 2026;33(4):128-136. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.4.128-136

Authors’ contribution: All authors made an equivalent contribution to the preparation of the publication.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Patient Consent for Publication: Written voluntary informed consent was obtained from patients for the publication of photographs, examination results, and treatment.

Keywords

About the Authors

Ekaterina A. Orlova, Dr. Sci. (Med.), Associate Professor, Head of the Department of Allergology and Immunology with a Course
in Dermatovenereology and Cosmetology, Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education; Professor, Department of General and Clinical Pharmacology, Penza State University, Penza, Russia; lisaorl@yandex.ru, ORCID:
https://orcid.org/0000-0002-3902-2018 (corresponding author)
Julia A. Kandrashkina, Cand. Sci. (Med.), Associate Professor, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology, Penza Institute for Advanced Medical Trainig – Branch of the Russian Medical Academy of Postgraduate Education; Associate Professor, Department of Obstetrics and Gynecology, Penza State University, Penza, Russia; novikova10l@mail.ru,
ORCID: https://orcid.org/0000-0002-5537-5729
Elena M. Kostina, Dr. Sci. (Med.), Associate Professor, Professor, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology, Penza Institute for Advanced Medical Trainig – Branch of the Russian Medical Academy of Postgraduate Education, Penza, Russia; elmihkostina@yandex.ru, ORCID: https://orcid.org/0000-0003-1797-8040
Maria N. Vikhreva, Assistant Professor, Department of Allergology and Immunology with a Course in Dermatovenereology and Cosmetology, Penza Institute for Advanced Medical Training – Branch of the Russian Medical Academy of Postgraduate Education, Penza, Russia; vichreva.87@mail.ru, ORCID: https://orcid.org/0009-0002-7977-5441

Similar Articles